U.S. next-generation therapy developer for obesity and metabolic disease Alveus raises $37.2 million in Series A+ financing, with investment from Novo Holdings and Jeito Capital
Summary
Alveus raised $37.2 million in Series A+ financing to advance its next-generation obesity and metabolic disease therapy program. The company is building treatments around high-selectivity amylin biology and aims to improve weight-loss durability, tolerability, and body composition. Novo Holdings and Jeito Capital joined the round, strengthening the company’s capital base. The article focuses on Alveus as a life sciences developer, so it is relevant to the ISV audience only at the broader pharma software taxonomy level rather than as a software vendor story.
Funding
Amount
$37.2M
Total raised
Date
June 3, 2026
Announcement date
Investors
Jeito Capital, Novo AS
Lead investors
Company
alveustx.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected